New scholarships worth EUR 332,000 awarded by Bayer Foundation to promote international talents

BayerThe Bayer Science & Education Foundation is making available approximately EUR 332,000 for 70 talented young people who wish to realize international study and vocational training projects. The new scholarship recipients are students of the natural sciences, agriculture and medicine, as well those training to become science teachers or young people from skilled non-academic professions. "We need dedicated and creative young scientists if we are to successfully shape the future. That's why with the Bayer Fellowship Program we are helping talented young people to participate in special study and continuing education projects abroad," says Kemal Malik, Bayer Management Board member responsible for Innovation.

The scholarship program follows the tradition of the Bayer scholarships initiated back in 1923 by Dr. Carl Duisberg, at that time Managing Director of the Bayer Group. Duisberg is regarded as a pioneer in the intensive cooperation between industry and universities, as well as in corporate social responsibility. Explains Dr. Carl-Heinz Duisberg, member of the Scientific Committee of the Bayer Fellowship Program and youngest grandchild of the program's founder: "My grandfather wanted to provide good training opportunities for young people because he saw this as a means of ensuring long-term benefits for society. He is also quoted as saying 'We must spend every spare penny on science - it is the best investment we can make.'"

Alongside the Otto Bayer, Jozef Schell and Carl Duisberg scholarships, the Bayer Fellowship Program also includes the Kurt Hansen and Hermann Strenger scholarships. The scholarships are targeted at students and vocational trainees in natural science and medical disciplines who would like to realize a particular foreign study project and require financial support for this. In addition to Germany-based applicants who would like to study abroad, the foundation supports scholarship recipients from outside of Germany who wish to realize a comparable project in Germany.

New in the Bayer Science & Education Foundation's program this year is an additional special budget for six selected students from African countries who are planning a project in Germany. Bayer's roots in Africa go back to 1920, when it first began marketing its products there. Today Bayer is represented throughout the continent, from Casablanca to Cape Town. The scholarships underline the mission of the Bayer foundation to work with young people and the next generation of scientists and opinion-leaders and to strengthen interest in the major challenges facing our society, such as health and agriculture.

Academic disciplines receiving support this year include the life sciences, chemistry, agriculture as well as human and veterinary medicine, with a total of 42 scholarships being awarded. Three Kurt Hansen scholarship recipients are also receiving assistance for teacher training in the natural sciences. Thanks to the Bayer scholarships, the new scholarship winners in the coming months will be able to implement their individual projects in 21 different countries: Argentina, Australia, Canada, China, Ethiopia, Iran, Ireland, Israel, Japan, New Zeeland, Norway, Poland, Singapore, South Africa, Spain, Sweden, Switzerland, Tunisia, Uganda, UK and the United States. Other scholarship recipients from Egypt, Jordan, Kenya, Lithuania, Nepal, the Netherlands, Portugal, Russia, Spain, South Africa and the United States will spend time studying in Germany.

The scholarships in the academic sector are being supplemented by Hermann Strenger scholarships to support young people looking to gain initial work experience abroad as part of a non-academic training program. This year, 19 young people from Germany are being supported who are planning a period abroad in Argentina, Australia, Canada, Ireland, Poland, Singapore, Spain, Sweden, Switzerland, Uganda, UK and in the United States, as part of their commercial, technical or health profession training.

The Bayer Science & Education Foundation thus is launching the ninth round of its funding program, which offers targeted support for scientific exchange and international work experience for young people. It targets creative, highly motivated and socially committed young people with above-average grades.

The next round of applications starts in June 2016.

Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the fields of health care, agriculture and high-tech polymer materials. As an innovation company, it sets trends in research-intensive areas. Bayer's products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2014, the Group employed 118,900 people and had sales of EUR 42.2 billion. Capital expenditures amounted to EUR 2.5 billion, R&D expenses to EUR 3.6 billion.

Most Popular Now

Fasenra (benralizumab) receives US FDA approval fo…

AstraZeneca and its global biologics research and development arm, MedImmune, announced that the US Food and Drug Administration (FDA) has approved Fasenra (benralizumab)...

Pfizer receives FDA approval for SUTENT® (sunitini…

Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration has approved a new indication expanding the use of SUTENT® (sunitinib malate) to include...

Alzheimer's disease might be a 'whole body' proble…

Alzheimer's disease, the leading cause of dementia, has long been assumed to originate in the brain. But research from the University of British Columbia and Chinese scie...

Cancer cells destroyed with dinosaur extinction me…

Cancer cells can be targeted and destroyed with the metal from the asteroid that caused the extinction of the dinosaurs, according to new research by an international col...

Novartis confirms leadership in multiple sclerosis…

Novartis today announced it will present 54 scientific abstracts from across its multiple sclerosis (MS) research portfolio at the 7th Joint European and Americas Committ...

Amgen and Novartis announce expanded collaboration…

Amgen (NASDAQ:AMGN) and Novartis announced an expanded collaboration with the Banner Alzheimer's Institute (BAI) to initiate a new trial - the Alzheimer's Prevention Init...

Transplanted hematopoietic stem cells reverse dama…

Researchers at University of California San Diego School of Medicine report that a single infusion of wildtype hematopoietic stem and progenitor cells (HSPCs) into a mous...

Novartis announces the planned acquisition of Adva…

Novartis announced today, that it has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to commence a tender...

'Precision Medicine' may not always be so precise

Precision Medicine in oncology, where genetic testing is used to determine the best drugs to treat cancer patients, is not always so precise when applied to some of the w...

New tissue-engineered blood vessel replacements on…

Researchers at the University of Minnesota have created a new lab-grown blood vessel replacement that is composed completely of biological materials, but surprisingly doe...

New US study reveals key reasons why millions of p…

Few of the more than 90 million Americans(1) with obesity are seeking and receiving long-term obesity care, according to new data from the Awareness, Care and Treatment I...

Efficacy and safety maintained in patients who swi…

Boehringer Ingelheim today announced one-year data from VOLTAIRE®-RA, a pivotal Phase III clinical trial comparing Cyltezo® (adalimumab-adbm) and reference product Humira...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]